Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.
Morgan Stanley expects the core monthly PCE rate to be 0.35%, rounding off to 0.4%, nudged higher by strong goods inflation and an acceleration in core services prices, excluding housing.
Wall Street dipped slightly on Thursday, with all major indexes edging into the red as investors digested President Donald Trump‘s latest move on auto tariffs.
Verint noted that ASC 606, a set of accounting rules governing how a company recognizes revenue from customer contracts, impacted its top- and bottom-line results.
At the Investor Day held in mid-January, the company said it has transitioned to a subscription model, with 80% of the revenue for the year coming from subscription offerings.
U.S. stocks decline on renewed tariff concerns, technology shares lead selloff while blue-chip stocks are more resilient. VIX jumps 8%, dollar and Treasury yields remain flat.
Raymond James said the adverse reaction of Lumen stock is due to the deal value being lower than the $6 billion to $9 billion stated by a Reuters report in December.
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025.
Wall Street’s recovery from its recent technical correction paused for a breather on Tuesday, as investors awaited more clarity on tariff developments and digested a downbeat consumer confidence report.
The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.
Wall Street soared Monday, kicking off the week in full risk-on mode as investors welcomed signs of easing trade tensions and stronger-than-expected economic data.
